Your browser doesn't support javascript.
loading
Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey.
Hartleb, Marek; Mastalerz-Migas, Agnieszka; Kowalski, Piotr; Okopien, Boguslaw; Popovic, Branko; Proga, Katarzyna; Cywinska-Durczak, Beata.
Afiliação
  • Hartleb M; Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice.
  • Mastalerz-Migas A; Department of Family Medicine, Wroclaw Medical University, Wroclaw.
  • Kowalski P; Department of Pharmaceutical Chemistry, Medical University of Gdansk, Gdansk.
  • Okopien B; Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
  • Popovic B; Consumer Health Care Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
  • Proga K; PEX PharmaSequence.
  • Cywinska-Durczak B; Consumer Health Care Scientific Affairs, Sanofi-Aventis Sp. z o.o, Warsaw, Poland.
Eur J Gastroenterol Hepatol ; 34(4): 426-434, 2022 04 01.
Article em En | MEDLINE | ID: mdl-34560694
ABSTRACT

BACKGROUND:

Nonalcoholic fatty liver disease (NAFLD) awareness is low. NAFLD diagnosis and management by gastroenterologists (GEs) and general practitioners (GPs) in Poland were evaluated.

METHODS:

RESTORE was an observational, noninterventional, retrospective cross-sectional survey performed among GEs and GPs with at least 3 years' experience. Computer-assisted web interviews were completed. GEs provided information from patient records.

RESULTS:

Mean experience was 14.2 (95 GEs) and 22.6 (115 GPs) years. Mean patient numbers with liver disorders consulted per month were 36 (13%; GEs) and 51 (6%; GPs); ~50% were patients with NAFLD. All GEs/GPs used ultrasound; most evaluated transaminases and gamma-glutamyl transferase. More GEs used other imaging techniques and a larger spectrum of laboratory tests than GPs. Physician-identified NAFLD key symptoms were similar for GEs/GPs. GEs noticed less obvious symptoms (abdominal discomfort, drowsiness, fatigability, lack of energy) vs. GPs (abdominal pain/discomfort, dyspepsia). Common comorbidities in NAFLD were similar in GE/GP responses. NAFLD interventions by GEs/GPs (% patients) were diet/lifestyle/pharmacological interventions (54%/59%), diet/lifestyle changes alone (41%/31%) or pharmacological interventions alone (5%/10%). The top three criteria for supportive pharmacological selection were efficacy, tolerability and quality of life improvement for GEs/GPs. The five supportive treatments most commonly prescribed by GEs/GPs were essential phospholipids, ursodeoxycholic acid, timonacic, silybinin/silymarin and ornithine + choline. Information from patient records (n = 380) confirmed GEs responses.

CONCLUSIONS:

NAFLD is not a silent disease as physicians and patients reported many, albeit nonspecific, symptoms. This cross-sectional survey provides important insights into clinical management of NAFLD by GEs and GPs in Poland.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clínicos Gerais / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clínicos Gerais / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article